Hyaluronic (HA) acid injections are used to mainly remove wrinkles from facial skin. However, injected HA and all non-permanent tissue fillers are absorbed in 1-6 months, limiting the benefit of the wrinkle treatment and leading to frequent re-injections. CosmetaLife, made of tiny injectable gel-particles configured to simulate skin, can provide a longer lasting treatment and a natural dermal correction by rejuvenating the skin to diminish, ameliorate, and repair the wrinkle through healing mechanisms.
Gel-Del® is focused on bringing CosmetaLife, its superior product for wrinkle treatment to the cosmetic augmentation market. This market already generates about $1 billion of annual revenue and is growing every year at increasing rates with little more than mediocre products (2011-12 increased >10%). Gel-Del's business plan includes the formation of the subsidiary CosmetaCorp, a cosmetic biomaterials company that designs and produces cosmetic augmentation products. After the CosmetaLife launch, CosmetaCorp expects to develop additional products in the cosmetic augmentation marketplace.
CosmetaLife is for investigational use and not yet approved by the FDA.
in 1 cc amounts for single-use injection.